▌ Indications
• Refractory type 2 diabetes (insulin resistance index ≥3.0)
• Genetic obesity (POMC/LEPR gene defects)
▌ Extended Indications
• Polycystic ovary syndrome (PCOS) with glucose metabolism abnormalities (OGTT 2h glucose reduction ≥2 mmol/L)
• Stage III diabetic nephropathy (UACR reduction ≥30%)
▌ Features & Clinical Trial Data
1、Triple-Target Mechanism:
•GLP-1R: Enhances glucose-dependent insulin secretion.
•GIPR: Central appetite suppression (40% reduction in hypothalamic NPY neuron activity).
•GCGR: Activates hepatic gluconeogenesis, 28% increase in basal metabolic rate (DEXA-verified).
2、Comparative Advantages:
•24-week HbA1c reduction: 2.4% vs. 1.9% for Tirzepatide (Δ=0.5%, P=0.013).
•Visceral fat reduction: 31% vs. 18% (MRI quantification).
3、Gastric Retention Controlled-Release Technology: 24-hour sustained release, peak-trough ratio <30% (vs. >50% for conventional tablets).
4、Pivotal Trial (n=1,327):
•52-week sustained weight loss: 30.1 kg (vs. 20.3 kg for Tirzepatide group).
•NASH improvement (≥2-grade): 58% (liver biopsy confirmed).
Reviews
There are no reviews yet.